David A. Siegel Biotechnology

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
ZNTL Zentalis Pharmaceuticals, Inc.	$138M	$2.7 Million 0.01% of portfolio	889,700	Q4 2024 Reduced 22.59%
RLAY Relay Therapeutics, Inc.	$481M	$2.63 Million 0.01% of portfolio	638,900	Q4 2024 Added 4.02%
CRBU Caribou Biosciences, Inc.	$82.1M	$2.34 Million 0.01% of portfolio	1,470,700	Q4 2024 Added 39.52%
LQDA Liquidia Corp	$1.04B	$2.14 Million 0.01% of portfolio	181,800	Q4 2024 Reduced 2.99%
KURA Kura Oncology, Inc.	$554M	$2.11 Million 0.01% of portfolio	242,200	Q4 2024 Added 147.15%
EDIT Editas Medicine, Inc.	$94.9M	$2.1 Million 0.01% of portfolio	1,657,000	Q4 2024 Added 46.77%
REPL Replimune Group, Inc.	$695M	$2.06 Million 0.0% of portfolio	170,400	Q4 2024 Reduced 9.55%
CDXS Codexis, Inc.	$282M	$1.93 Million 0.0% of portfolio	403,700	Q4 2024 Reduced 16.78%
MDXG Mimedx Group, Inc.	$954M	$1.92 Million 0.0% of portfolio	199,300	Q4 2024 Reduced 33.05%
CABA Cabaletta Bio, Inc.	$78.6M	$1.83 Million 0.0% of portfolio	831,900	Q4 2024 Added 195.84%
DYN Dyne Therapeutics, Inc.	$720M	$1.79 Million 0.0% of portfolio	76,100	Q4 2024 Added 25.37%
PLRX Pliant Therapeutics, Inc.	$148M	$1.79 Million 0.0% of portfolio	135,700	Q4 2024 Reduced 14.01%
BMEA Biomea Fusion, Inc.	$109M	$1.78 Million 0.0% of portfolio	459,500	Q4 2024 Added 290.73%
ABSI Absci Corp	$540M	$1.77 Million 0.0% of portfolio	676,400	Q4 2024 Added 191.93%
VTYX Ventyx Biosciences, Inc.	$96.7M	$1.75 Million 0.0% of portfolio	800,800	Q4 2024 Added 72.07%
AVIR Atea Pharmaceuticals, Inc.	$262M	$1.65 Million 0.0% of portfolio	493,600	Q4 2024 Reduced 15.25%
VERV Verve Therapeutics, Inc.	$514M	$1.65 Million 0.0% of portfolio	293,200	Q4 2024 Added 58.83%
FULC Fulcrum Therapeutics, Inc.	$192M	$1.61 Million 0.0% of portfolio	343,600	Q4 2024 Reduced 10.1%
SEER Seer, Inc.	$135M	$1.58 Million 0.0% of portfolio	681,900	Q4 2024 Added 24.19%
ERAS Erasca, Inc.	$192M	$1.49 Million 0.0% of portfolio	594,600	Q4 2024 Reduced 25.04%
NRIX Nurix Therapeutics, Inc.	$829M	$1.49 Million 0.0% of portfolio	79,100	Q4 2024 Added 33.84%
DSGN Design Therapeutics, Inc.	$228M	$1.44 Million 0.0% of portfolio	233,900	Q4 2024 Reduced 23.29%
SAVA Cassava Sciences Inc	$97M	$1.43 Million 0.0% of portfolio	606,700	Q4 2024 New
RGNX Regenxbio Inc.	$316M	$1.39 Million 0.0% of portfolio	180,000	Q4 2024 Added 164.71%
NKTR Nektar Therapeutics	$184M	$1.38 Million 0.0% of portfolio	1,486,242	Q4 2024 Reduced 0.93%
ALXO Alx Oncology Holdings Inc	$44.8M	$1.38 Million 0.0% of portfolio	823,900	Q4 2024 Added 64.62%
FATE Fate Therapeutics Inc	$138M	$1.37 Million 0.0% of portfolio	828,100	Q4 2024 Reduced 10.69%
DAWN Day One Biopharmaceuticals, Inc.	$901M	$1.35 Million 0.0% of portfolio	106,600	Q4 2024 Reduced 7.38%
TECH Bio Techne Corp	$2.59B	$1.29 Million 0.0% of portfolio	17,900	Q4 2024 Reduced 4.79%
VRTX Vertex Pharmaceuticals Inc	$118B	$1.29 Million 0.0% of portfolio	3,200	Q4 2024 Reduced 89.12%
NUVB Nuvation Bio Inc.	$493M	$1.27 Million 0.0% of portfolio	476,400	Q4 2024 Reduced 10.77%
HRTX Heron Therapeutics, Inc.	$211M	$1.26 Million 0.0% of portfolio	823,871	Q4 2024 Added 1.54%
SVRA Savara Inc	$322M	$1.2 Million 0.0% of portfolio	390,715	Q4 2024 Added 34.77%
MRVI Maravai Lifesciences Holdings, Inc.	$552M	$1.18 Million 0.0% of portfolio	216,500	Q4 2024 Reduced 67.66%
AKRO Akero Therapeutics, Inc.	$2.35B	$1.14 Million 0.0% of portfolio	41,100	Q4 2024 Added 195.68%
PHAT Phathom Pharmaceuticals, Inc.	$226M	$1.09 Million 0.0% of portfolio	133,700	Q4 2024 New
PMVP Pmv Pharmaceuticals, Inc.	$63.4M	$1.08 Million 0.0% of portfolio	714,600	Q4 2024 Reduced 4.87%
FOLD Amicus Therapeutics, Inc.	$2.74B	$1.05 Million 0.0% of portfolio	111,976	Q4 2024 Added 86.7%
GOSS Gossamer Bio, Inc.	$123M	$1.04 Million 0.0% of portfolio	1,157,500	Q4 2024 Added 44.69%
STRO Sutro Biopharma, Inc.	$93.4M	$1.01 Million 0.0% of portfolio	547,800	Q4 2024 Reduced 7.29%
ADGI Adagio Therapeutics, Inc.	$505M	$1.01 Million 0.0% of portfolio	304,200	Q4 2024 Added 1,276.47%
AMLX Amylyx Pharmaceuticals, Inc.	$212M	$910,000 0.0% of portfolio	241,400	Q4 2024 Reduced 22.0%
ENTA Enanta Pharmaceuticals Inc	$148M	$898,000 0.0% of portfolio	156,300	Q4 2024 Reduced 32.92%
VRNA Verona Pharma PLC	$3.91B	$882,000 0.0% of portfolio	19,000	Q4 2024 New
RCUS Arcus Biosciences, Inc.	$945M	$875,000 0.0% of portfolio	58,800	Q4 2024 Added 35.8%
ETNB 89bio, Inc.	$491M	$859,000 0.0% of portfolio	112,100	Q4 2024 Reduced 31.31%
ABOS Acumen Pharmaceuticals, Inc.	$58.7M	$858,000 0.0% of portfolio	499,100	Q4 2024 Added 6.4%
WVE Wave Life Sciences Ltd.	$939M	$842,000 0.0% of portfolio	68,100	Q4 2024 New
AMRN Amarin Corp Plcuk	$246M	$834,000 0.0% of portfolio	1,739,300	Q4 2024 Reduced 11.98%
ALEC Alector, Inc.	$140M	$812,000 0.0% of portfolio	429,900	Q4 2024 Added 8.86%

Shares Options

David A. Siegel

David A. Siegel is the co-founder and CEO of Two Sigma Advisers, a successful investment firm that uses technology and data-driven approaches to investing. Siegel is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track David A. Siegel's portfolio

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account